Subtype
Endometrial Neoplasm
CI-CAN-00007648Explore in graph →
Non-malignant400 active trials4 approved drugs28 evidence items
Loading cancer entity…
Subtype
CI-CAN-00007648Explore in graph →
Clinical trials
1,340 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00033358 | Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00025467 | Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00107445 | EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00050440 | Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma | completed | Phase 2 | 50 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 4 | Jan 8, 2013 | clinicaltrials |
| NCT00003939 | Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma | completed | Phase 2 | 132 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Sep 24, 2012 | clinicaltrials |
| NCT00006357 | STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 91 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Sep 24, 2012 | clinicaltrials |
| NCT00022620 | Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer | completed | Phase 2 | — | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Sep 24, 2012 | clinicaltrials |
| NCT00052312 | Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer | completed | Phase 2 | 141 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Sep 24, 2012 | clinicaltrials |
| NCT00392769 | Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer | completed | Phase 2 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 6, 2012 | clinicaltrials |
| NCT00334295 | Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. | completed | Phase 2 | 35 | AstraZenecaINDUSTRY | 1 | Jul 31, 2012 | clinicaltrials |
| NCT00505739 | Mifepristone for Patients With Endometrial Cancer and LGESS | completed | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2012 | clinicaltrials |
| NCT00267488 | Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer | completed | Phase 2 | 70 | GlaxoSmithKlineINDUSTRY | 3 | Jul 11, 2012 | clinicaltrials |
| NCT00003127 | S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer | completed | Phase 2 | 57 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 14, 2012 | clinicaltrials |
| NCT00003669 | Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer | completed | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Jun 7, 2012 | clinicaltrials |
| NCT00004915 | Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer | completed | Phase 2 | — | Northwestern UniversityOTHER | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00032162 | Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer | completed | Phase 1 / Phase 2 | 63 | AGO Study GroupOTHER | 1 | May 31, 2012 | clinicaltrials |
| NCT00333086 | A Study of Letrozole in the Treatment of Endometrial Cancer | completed | Phase 2 | 36 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 19, 2012 | clinicaltrials |
| NCT00607607 | A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer | completed | Phase 2 | 44 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00569257 | Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors | completed | Phase 2 | 85 | AEterna ZentarisINDUSTRY | 2 | Dec 13, 2011 | clinicaltrials |
| NCT00249990 | Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) | completed | Phase 2 | 39 | University of New MexicoOTHER | 1 | Jan 7, 2010 | clinicaltrials |
| NCT00377520 | A Trial for Patients With Advanced/Recurrent Endometrial Cancer | completed | Phase 2 | 27 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 20, 2009 | clinicaltrials |
| NCT00612495 | Endometrial Cancer - LOHP Alone and With 5FU | completed | Phase 2 | 31 | SanofiINDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00401635 | END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin | completed | Phase 2 | 42 | National Cancer Institute, NaplesOTHER | 1 | Sep 5, 2007 | clinicaltrials |
| NCT00010829 | Macrobiotic Diet and Flax Seed: Effects on Estrogens, Phytoestrogens, & Fibrinolytic Factors | completed | Phase 2 | — | National Center for Complementary and Integrative Health (NCCIH)NIH | 1 | Aug 18, 2006 | clinicaltrials |
Data updated 23 days agoSource updated May 3, 2013source: clinicaltrials